Could an Alzheimer's drug slow Parkinson's? new trial aims to find out.
NCT ID NCT07544953
First seen Apr 25, 2026 · Last updated Apr 25, 2026
Summary
This study tests whether lecanemab, an FDA-approved Alzheimer's drug, can clear amyloid plaques in the brains of people with Parkinson's disease who also have early Alzheimer's pathology. About 60 adults aged 50-90 with mild cognitive impairment or early dementia will receive lecanemab for 18 months. The goal is to see if reducing amyloid buildup can slow Parkinson's progression, for which no disease-slowing treatments currently exist.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Yonsei University College of Medicine
Seoul, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.